Form 4: Madrigal Pharmaceuticals CEO Sells Shares to Cover Tax Obligations

Madrigal Pharmaceuticals CEO William John Sibold sold 1,584 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• William John Sibold, the President and CEO of Madrigal Pharmaceuticals, sold 1,584 shares of common stock on January 24, 2025.
• The sale was executed at a price of $335.24 per share.
• This transaction was not at the discretion of Mr. Sibold, but rather an automatic sale by the issuer to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Mr. Sibold beneficially owns 54,303 shares of Madrigal Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, and is common practice for executives who receive stock-based compensation.

Comparison to Industry Standards

• Stock sales by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, which often trigger tax liabilities upon vesting.
• The sale of shares to cover these liabilities is a standard procedure and does not necessarily indicate a change in the executive's outlook on the company's future.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, William John Sibold, stock sale, insider trading, tax obligations, restricted stock units, executive compensation